And the last two paragraphs of a Motley Fool summary of today's...

And the last two paragraphs of  a Motley Fool summary of today's SPL announcement reads:

"But while this is undoubtedly promising news for all involved and could mean Starpharma has a bright future ahead of it, it is worth remembering that there is still a long road ahead before the company comes close to generating revenue from DEP docetaxel.

In light of this, I would suggest investors keep Starpharma on their watchlist and consider an investment in industry behemoth CSL Limited (ASX: CSL) for now instead."

Bahahahaaa. MF continue to have no idea. Yes subscribers, wait until the company has ZERO risk left before a little purchase of SPL shares at multiples of today's closing price. Fools.